Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00006471
First received: November 6, 2000
Last updated: July 27, 2012
Last verified: July 2012

November 6, 2000
July 27, 2012
September 2000
July 2004   (final data collection date for primary outcome measure)
To determine the response rate, time to progression, median survival, and percent one-year survival [ Time Frame: one-year survival ] [ Designated as safety issue: Yes ]
To determine the response rate, time to progression, median survival, and percent one-year survival.
Not Provided
Complete list of historical versions of study NCT00006471 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
A Phase II Study of Fenretinide in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of fenretinide in treating patients who have recurrent or metastatic head and neck cancer.

OBJECTIVES:

  • Determine the response rate, time to progression, median survival, and percent of 1-year survival in patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with fenretinide.
  • Determine the pharmacokinetics and safety of this drug in these patients.

OUTLINE: Patients receive oral fenretinide every 12 hours on days 1-7. Treatment repeats every 3 weeks for at least 3 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response continue treatment for 1 year.

PROJECTED ACCRUAL: A total of 16-35 patients will be accrued for this study.

Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Head and Neck Cancer
Drug: Fenretinide
1800 mg/m2 per day for seven consecutive days, in two divided doses of 900 mg/m2 12 hours apart, repeated every 3 weeks.
Other Name: 4-HPR
Experimental: Fenretinide
Intervention: Drug: Fenretinide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
11
July 2004
July 2004   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Biopsy-proven recurrent squamous cell carcinoma of the head and neck
  2. Stage 4 disease, either at initial presentation or at recurrence. Patients with metastatic disease at initial presentation must have received at least one prior course of cytotoxic chemotherapy.
  3. Patients who present with metastatic disease should have received no more than one prior regimen of chemotherapy or biologic therapy to be eligible. Patients who initially received adjuvant or induction chemotherapy and then recurred may have received one additional cycle of chemotherapy or biologic therapy at the time of recurrence. Patients may have received any number of cycles of a particular regimen of chemotherapy.
  4. Patients must have a life expectancy of at least 3 months
  5. Biopsy of the recurrent lesion(s) is encouraged but not mandatory for enrollment.
  6. Performance status grade 0-2.
  7. Serum creatinine <= 1.5 mg/dL.
  8. Serum transaminases and bilirubin <= 1.5 time normal.
  9. Age >= 18 years.
  10. White blood cell count >= 3,000; platelets >= 100,000; hemoglobin >= 9mg/dl.
  11. Signed informed consent.
  12. Women of childbearing potential must agree to utilize two methods of effective birth control, one barrier, one hormonal, or should abstain from sexual intercourse that could result in pregnancy. Contraceptive measures should be continued for at least one month after fenretinide administration has been discontinued.
  13. It is recommended that male patients with female partners of childbearing potential use barrier contraception while on fenretinide.

Exclusion Criteria:

  1. Pregnant women (women of childbearing potential must have a negative pregnancy test within 24 hours prior to enrollment in the study); women who are currently breast-feeding.
  2. Grade 2 or greater peripheral neuropathy
  3. Concurrent treatment with cytotoxic chemotherapy or radiation
  4. Serious infection or other intercurrent illness requiring immediate therapy.
  5. Inability to take oral medications, or other medical or social factors interfering with compliance.
  6. Patients on high dose synthetic or natural Vitamin A derivatives (>= 10,000 per day).
  7. Patients should not take any anti-oxidants such as Vitamin C or E.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00006471
ID99-334, U01CA070172, P30CA016672, MDA-ID-99334, NCI-610, CDR0000068294
Yes
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Study Chair: Bonnie S. Glisson, MD M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP